Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial
- PMID: 22901887
- DOI: 10.1016/S0140-6736(12)60953-2
Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial
Abstract
Background: Azithromycin is a macrolide antibiotic with anti-inflammatory and immunomodulatory properties. We tested the hypothesis that azithromycin would decrease the frequency of exacerbations, increase lung function, and improve health-related quality of life in patients with non-cystic fibrosis bronchiectasis.
Methods: We undertook a randomised, double-blind, placebo-controlled trial at three centres in New Zealand. Between Feb 12, 2008, and Oct 15, 2009, we enrolled patients who were 18 years or older, had had at least one pulmonary exacerbation requiring antibiotic treatment in the past year, and had a diagnosis of bronchiectasis defined by high-resolution CT scan. We randomly assigned patients to receive 500 mg azithromycin or placebo three times a week for 6 months in a 1:1 ratio, with a permuted block size of six and sequential assignment stratified by centre. Participants, research assistants, and investigators were masked to treatment allocation. The coprimary endpoints were rate of event-based exacerbations in the 6-month treatment period, change in forced expiratory volume in 1 s (FEV(1)) before bronchodilation, and change in total score on St George's respiratory questionnaire (SGRQ). Analyses were by intention to treat. This study is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12607000641493.
Findings: 71 patients were in the azithromycin group and 70 in the placebo group. The rate of event-based exacerbations was 0·59 per patient in the azithromycin group and 1·57 per patient in the placebo group in the 6-month treatment period (rate ratio 0·38, 95% CI 0·26-0·54; p<0·0001). Prebronchodilator FEV(1) did not change from baseline in the azithromycin group and decreased by 0·04 L in the placebo group, but the difference was not significant (0·04 L, 95% CI -0·03 to 0·12; p=0·251). Additionally, change in SGRQ total score did not differ between the azithromycin (-5·17 units) and placebo groups (-1·92 units; difference -3·25, 95% CI -7·21 to 0·72; p=0·108).
Interpretation: Azithromycin is a new option for prevention of exacerbations in patients with non-cystic fibrosis bronchiectasis with a history of at least one exacerbation in the past year.
Funding: Health Research Council of New Zealand and Auckland District Health Board Charitable Trust.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Comment in
-
Azithromycin in bronchiectasis: when should it be used?Lancet. 2012 Aug 18;380(9842):627-9. doi: 10.1016/S0140-6736(12)61261-6. Lancet. 2012. PMID: 22901872 No abstract available.
-
Azithromycin in non-cystic-fibrosis bronchiectasis.Lancet. 2013 Jan 5;381(9860):27. doi: 10.1016/S0140-6736(13)60013-6. Lancet. 2013. PMID: 23290963 No abstract available.
-
Azithromycin in non-cystic-fibrosis bronchiectasis - Authors' reply.Lancet. 2013 Jan 5;381(9860):27. doi: 10.1016/S0140-6736(13)60014-8. Lancet. 2013. PMID: 23290964 No abstract available.
Similar articles
-
Efficacy of oral amoxicillin-clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial.Lancet Respir Med. 2019 Sep;7(9):791-801. doi: 10.1016/S2213-2600(19)30254-1. Epub 2019 Aug 16. Lancet Respir Med. 2019. PMID: 31427252 Free PMC article. Clinical Trial.
-
Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial.JAMA. 2013 Mar 27;309(12):1251-9. doi: 10.1001/jama.2013.1937. JAMA. 2013. PMID: 23532241 Clinical Trial.
-
Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial.Lancet Respir Med. 2013 Oct;1(8):610-620. doi: 10.1016/S2213-2600(13)70185-1. Epub 2013 Sep 17. Lancet Respir Med. 2013. PMID: 24461664 Clinical Trial.
-
The efficacy of azithromycin to prevent exacerbation of non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled studies.J Cardiothorac Surg. 2022 Oct 11;17(1):266. doi: 10.1186/s13019-022-01882-y. J Cardiothorac Surg. 2022. PMID: 36221151 Free PMC article. Review.
-
Assessing effects of inhaled antibiotics in adults with non-cystic fibrosis bronchiectasis--experiences from recent clinical trials.Expert Rev Respir Med. 2018 Sep;12(9):769-782. doi: 10.1080/17476348.2018.1503540. Epub 2018 Aug 3. Expert Rev Respir Med. 2018. PMID: 30025482 Review.
Cited by
-
Primary ciliary dyskinesia.Semin Respir Crit Care Med. 2015 Apr;36(2):169-79. doi: 10.1055/s-0035-1546748. Epub 2015 Mar 31. Semin Respir Crit Care Med. 2015. PMID: 25826585 Free PMC article. Review.
-
Bronchiectasis exacerbation study on azithromycin and amoxycillin-clavulanate for respiratory exacerbations in children (BEST-2): study protocol for a randomized controlled trial.Trials. 2013 Feb 20;14:53. doi: 10.1186/1745-6215-14-53. Trials. 2013. PMID: 23421781 Free PMC article. Clinical Trial.
-
The bacterial microbiota in inflammatory lung diseases.Clin Immunol. 2015 Aug;159(2):177-82. doi: 10.1016/j.clim.2015.05.022. Epub 2015 Jun 26. Clin Immunol. 2015. PMID: 26122174 Free PMC article. Review.
-
Management of Busulfan-Induced Lung Injury in Pediatric Patients with High-Risk Neuroblastoma.J Clin Med. 2024 Oct 8;13(19):5995. doi: 10.3390/jcm13195995. J Clin Med. 2024. PMID: 39408056 Free PMC article.
-
Brazilian consensus on non-cystic fibrosis bronchiectasis.J Bras Pneumol. 2019 Aug 12;45(4):e20190122. doi: 10.1590/1806-3713/e20190122. J Bras Pneumol. 2019. PMID: 31411280 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous